硫酸镁用于 imminent 早产风险胎儿的神经保护:系统评价、meta 分析与试验序贯分析
该系统评价纳入 6 项 RCT(5917 名女性),评估 imminent 早产风险孕妇使用硫酸镁对子代脑瘫的神经保护作用。Meta 分析显示硫酸镁降低子代脑瘫风险(RR 0.68, 95% CI 0.54-0.85),试验序贯分析结果一致(RR 0.69, 95% CI 0.48-0.97),结论明确。
要点
- imminent 早产风险孕妇使用硫酸镁可降低子代脑瘫风险。
- Meta 分析 RR 0.68(95% CI 0.54-0.85),试验序贯分析 RR 0.69(95% CI 0.48-0.97)。
- 证据质量采用 GRADE 评估,方案已在 PROSPERO 注册(CRD42019151441)。
核心结论
- 硫酸镁用于 imminent 早产风险孕妇可明确降低子代脑瘫风险。
研究设计与样本
- 系统评价与 meta 分析,纳入 6 项 RCT,共 5917 名女性。
- 采用固定效应模型计算汇总 RR 和 95% CI,并对主要结局脑瘫进行试验序贯分析。
- 证据质量采用 GRADE 评估,方案在 PROSPERO 注册(CRD42019151441)。
主要发现
- Meta 分析显示硫酸镁降低子代脑瘫风险(RR 0.68, 95% CI 0.54-0.85)。
- 试验序贯分析显示硫酸镁降低子代脑瘫风险(RR 0.69, 95% CI 0.48-0.97)。
临床怎么用
- 对 imminent 早产风险孕妇可考虑使用硫酸镁以降低子代脑瘫风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ordinary meta-analyses indicate that magnesium sulphate (MgSO4 ) treatment in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral palsy (CP). However, repetitive testing of cumulative data calls for statistical caution, e.g. by trial sequential analysis (TSA), for which there are previously insufficient samples to draw a firm conclusion. Recently, a randomised controlled trial (RCT) provided additional data that potentially increased the sample size such that a new TSA might detect a statistically significant effect. OBJECTIVES: To assess the possible fetal neuroprotective effect of MgSO4 for women at imminent risk for preterm delivery in an updated systematic review with meta-analysis and TSA. SEARCH STRATEGY: We searched MEDLINE, Embase, Cochrane and ClinicalTrials.gov on 8 October 2019. The search strategy clustered terms describing the MgSO4 intervention and preterm delivery. SELECTION CRITERIA: RCTs. DATA COLLECTION AND ANALYSIS: Two reviewers extracted the data. Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using fixed-effects models. A TSA was applied to the primary outcome, CP. The quality of the evidence was assessed using GRADE. The protocol was registered in PROSPERO (registration: CRD42019151441). MAIN RESULTS: We identified six eligible trials (5917 women). MgSO4 intervention in women at imminent risk for preterm birth decreased the offspring's CP risk (meta-analysis RR 0.68, 95% CI 0.54-0.85; TSA RR 0.69, 95% CI 0.48-0.97). CONCLUSIONS: This systematic review with meta-analysis and TSA shows conclusively that MgSO4 , when given to women at imminent risk for preterm delivery, decreases the offspring's CP risk. TWEETABLE ABSTRACT: Antenatal magnesium sulphate decreases the risk of cerebral palsy in children born preterm.
引用
- Wolf HT, Huusom LD, Henriksen TB, et al. Magnesium sulphate for fetal neuroprotection at imminent risk for preterm delivery: a systematic review with meta-analysis and trial sequential analysis. BJOG. 2020. PMID: 32237069. doi:10.1111/1471-0528.16238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。